DashboardPortfoliosWatchlistCommunityDiscoverScreener
NOT FOR DISTRIBUTION

Physiomics Plc

AIM:PYC Stock Report

Market Cap: UK£2.4m

  • Company Overview
  • Valuation
  • Future Growth
  • Past Performance
  • Financial Health
  • Dividend
  • Management
  • Ownership
  • Other Information
  • Stock Community

Physiomics Past Earnings Performance

Past criteria checks 0/6

Physiomics's earnings have been declining at an average annual rate of -22.8%, while the Life Sciences industry saw earnings declining at 4.5% annually. Revenues have been declining at an average rate of 1.7% per year.

Key information

-22.77%

Earnings growth rate

-5.86%

EPS growth rate

Life Sciences Industry Growth36.86%
Revenue growth rate-1.67%
Return on equity-123.47%
Net Margin-48.13%
Last Earnings Update31 Dec 2025

Recent past performance updates

Recent updates

Analysis Article • Nov 15

It's Unlikely That Shareholders Will Increase Physiomics Plc's (LON:PYC) Compensation By Much This Year

Key Insights Physiomics will host its Annual General Meeting on 21st of November Total pay for CEO Jim Millen includes...
Analysis Article • Nov 17

Here's Why We Think Physiomics Plc's (LON:PYC) CEO Compensation Looks Fair

The performance at Physiomics Plc ( LON:PYC ) has been rather lacklustre of late and shareholders may be wondering what...
Analysis Article • Nov 16

Here's Why Shareholders Will Not Be Complaining About Physiomics Plc's (LON:PYC) CEO Pay Packet

It would be hard to discount the role that CEO Jim Millen has played in delivering the impressive results at Physiomics...
Analysis Article • Feb 08

What Can We Conclude About Physiomics' (LON:PYC) CEO Pay?

Jim Millen became the CEO of Physiomics Plc ( LON:PYC ) in 2016, and we think it's a good time to look at the...

Revenue & Expenses Breakdown

How Physiomics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

AIM:PYC Revenue, expenses and earnings (GBP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 251000
30 Sep 251000
30 Jun 251000
31 Mar 251-100
31 Dec 241-100
30 Sep 241-100
30 Jun 241-100
31 Mar 241-100
31 Dec 231000
30 Sep 231000
30 Jun 231000
31 Mar 231000
31 Dec 221000
30 Sep 221000
30 Jun 221000
31 Mar 221000
31 Dec 211000
30 Sep 211000
30 Jun 211000
31 Mar 211000
31 Dec 201000
30 Sep 201000
30 Jun 201000
31 Mar 201000
31 Dec 191000
30 Sep 191000
30 Jun 191000
31 Mar 191000
31 Dec 181000
30 Sep 181000
30 Jun 181000
31 Mar 180000
31 Dec 170000
30 Sep 170000
30 Jun 170000
31 Mar 170000
31 Dec 160000
30 Sep 160000
30 Jun 160000
31 Mar 160000
31 Dec 150000
30 Sep 150000

Quality Earnings: PYC is currently unprofitable.

Growing Profit Margin: PYC is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: PYC is unprofitable, and losses have increased over the past 5 years at a rate of 22.8% per year.

Accelerating Growth: Unable to compare PYC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PYC is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (11.5%).


Return on Equity

High ROE: PYC has a negative Return on Equity (-123.47%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/11 17:53
End of Day Share Price 2026/09/11 00:00
Earnings2025/12/31
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
  • SEC Form 10-K
  • SEC Form 10-Q
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
  • Analyst Research Reports
  • Blue Matrix
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
  • ICE Market Data
  • SEC Form S-1
Ownership10 years
  • Top shareholders
  • Insider trading
  • SEC Form 4
  • SEC Form 13D
Management10 years
  • Leadership team
  • Board of directors
  • SEC Form 10-K
  • SEC Form DEF 14A
Key Developments10 years
  • Company announcements
  • SEC Form 8-K

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Physiomics Plc is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jonathan LevinsonHybridan LLP

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide